At 9.4% CAGR, the Asia Pacific Home Infusion Therapy Market is projected to be worth US$ 5,725.65 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific home infusion therapy market was valued at US$ 3,340.35 million in 2022 and is expected to reach US$ 5,725.65 million by 2028, registering a CAGR of 9.4% from 2022 to 2028. Reduction in duration of hospital stays and cost of care and increasing incidences of chronic disorders coupled with rising geriatric population are the critical factors attributed to the Asia Pacific home infusion therapy market expansion.

With a dramatic shift toward homecare during the COVID-19 pandemic, the pharmaceutical and medical industries are focusing on developing various types of drugs to be administered in homecare settings, through the combination of pumps and professional services. The International Agency for Research on Cancer (IARC) estimated that 19.3 million new cases of cancer occurred globally in 2020 and caused ~10 million deaths. The past decades have witnessed a shift in the delivery of chemotherapy from the hospital inpatient setting to the hospital outpatient setting to the specialized community practice setting. Furthermore, with developments in healthcare, a homecare setting is likely to become the place of care for the infusion of chemotherapy drugs.

Rockwell Medical also initiated a clinical development program with FPC to treat iron deficiency anemia (IDA) in the home infusion setting. The Phase II study will be the first-ever randomized controlled trial of parenteral iron in the home infusion setting. Home infusion of traditional macromolecular IV iron is limited due to the risk of hypersensitivity, the need for medical supervision of the injection, and concerns about incompatibility with other infused drugs. An office visit for an infusion of IV iron is expensive and often does not fit the physician practice care model.

Companies in the home infusion therapy market are working on expanding their business by focusing on the unmet needs of patients. Globally, ~380 marketed infusion drugs and an additional 160 drugs are currently in the Phase 3 of drug development; more than 70% of these have an oncology or hematology indication. Thus, with growing efforts to launch infusion therapies for providing treatment of cancer and IDA at home is likely to fuel the home infusion therapy market growth during the forecast period.  

On the contrary, recalls of infusion pumps and safety concerns associated with home infusion hurdles the growth of Asia Pacific home infusion therapy market.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held 56.6% market share in 2022, amassing US$ 1885.55 million. It is projected to garner US$ 3276.94 million by 2028 to expand at 9.6% CAGR during 2022–2028.  

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held 25.1% market share in 2022, amassing US$ 838.23 million. It is projected to garner US$ 1,444.47 million by 2028 to expand at 9.5% CAGR during 2022–2028.    

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held 75.7% market share in 2022, amassing US$ 2,529.14 million. It is projected to garner US$ 4,390.51 million by 2028 to expand at 9.6% CAGR during 2022–2028.    

Based on country, the Asia Pacific home infusion therapy market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.6% market share in 2022. It was assessed at US$ 977.05 million in 2022 and is likely to hit US$ 1,657.57 million by 2028, exhibiting a CAGR of 9.2% during the forecast period.

Key players dominating the Asia Pacific home infusion therapy market are B. Braun Melsungen AG; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; JMS Co Ltd; Terumo Corp, among others.         

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com